EG24533A - Piperdine derivatives useful as CCR 5 antagonists - Google Patents
Piperdine derivatives useful as CCR 5 antagonistsInfo
- Publication number
- EG24533A EG24533A EG20000563A EG20000563A EG24533A EG 24533 A EG24533 A EG 24533A EG 20000563 A EG20000563 A EG 20000563A EG 20000563 A EG20000563 A EG 20000563A EG 24533 A EG24533 A EG 24533A
- Authority
- EG
- Egypt
- Prior art keywords
- ccr
- antagonists
- derivatives useful
- piperdine derivatives
- piperdine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30518799A | 1999-05-04 | 1999-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
EG24533A true EG24533A (en) | 2009-08-30 |
Family
ID=23179704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EG20000563A EG24533A (en) | 1999-05-04 | 2000-05-02 | Piperdine derivatives useful as CCR 5 antagonists |
Country Status (32)
Country | Link |
---|---|
EP (2) | EP1659111A3 (pl) |
JP (3) | JP3894729B2 (pl) |
KR (1) | KR100439357B1 (pl) |
CN (2) | CN1524527A (pl) |
AR (1) | AR023939A1 (pl) |
AT (1) | ATE299866T1 (pl) |
AU (2) | AU780983B2 (pl) |
BR (1) | BR0010607A (pl) |
CA (1) | CA2371587C (pl) |
CO (1) | CO5170522A1 (pl) |
CZ (1) | CZ301161B6 (pl) |
DE (1) | DE60021371T2 (pl) |
DK (1) | DK1175402T3 (pl) |
EG (1) | EG24533A (pl) |
ES (1) | ES2246233T3 (pl) |
HK (1) | HK1039330B (pl) |
HU (1) | HUP0203528A3 (pl) |
IL (1) | IL145742A0 (pl) |
MY (1) | MY141473A (pl) |
NO (1) | NO322044B1 (pl) |
NZ (1) | NZ514675A (pl) |
PE (1) | PE20010113A1 (pl) |
PL (1) | PL203117B1 (pl) |
PT (1) | PT1175402E (pl) |
RU (2) | RU2266281C2 (pl) |
SA (1) | SA00210270B1 (pl) |
SI (1) | SI1175402T1 (pl) |
SK (1) | SK286968B6 (pl) |
TR (2) | TR200103213T2 (pl) |
TW (1) | TWI283666B (pl) |
WO (1) | WO2000066559A1 (pl) |
ZA (1) | ZA200108867B (pl) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
US20050065319A1 (en) * | 2000-12-19 | 2005-03-24 | Baroudy Bahige M. | Combination method for treating viral infections |
SI1373256T1 (sl) * | 2001-03-29 | 2005-12-31 | Schering Corp | Antagonisti CCR5, uporabni pri zdravljenju AIDS-a |
GB0108876D0 (en) * | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
IL159256A0 (en) * | 2001-07-02 | 2004-06-01 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
AR036366A1 (es) * | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
US6914142B2 (en) | 2001-10-15 | 2005-07-05 | Schering Corporation | Synthesis of (4-bromopnenyl)(4-piperidyl)methanone-(Z)-O-ethyloxime and salts |
US6818773B2 (en) * | 2001-10-15 | 2004-11-16 | Schering Corporation | Synthesis of 4-[(Z)-4-bromophenyl)(ethoxyimino) methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbony)]-4'-methyl-1,4-′bipiperidine |
CA2467555A1 (en) * | 2001-11-29 | 2003-08-14 | Schering Corporation | Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl)-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-me thyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections |
EP2311818B1 (en) | 2002-02-28 | 2013-01-16 | Novartis AG | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
SE0200843D0 (sv) * | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
CN100396676C (zh) * | 2002-03-29 | 2008-06-25 | 先灵公司 | 作为ccr5拮抗药的哌啶和哌嗪化合物的合成 |
CA2483253A1 (en) * | 2002-04-24 | 2003-11-06 | Takeda Pharmaceutical Company Limited | Use of compounds having ccr antagonism |
JP2004107298A (ja) * | 2002-09-20 | 2004-04-08 | Takeda Chem Ind Ltd | ウレア化合物およびその用途 |
WO2004026833A1 (ja) * | 2002-09-20 | 2004-04-01 | Takeda Pharmaceutical Company Limited | 環状アミン化合物、その製造法および用途 |
GB0223223D0 (en) * | 2002-10-07 | 2002-11-13 | Novartis Ag | Organic compounds |
MXPA05006354A (es) * | 2002-12-13 | 2005-08-26 | Smithkline Beecham Corp | Antagonistas ccr5 como agentes terapeuticos. |
PE20040769A1 (es) * | 2002-12-18 | 2004-11-06 | Schering Corp | Derivados de piperidina utiles como antagonisas ccr5 |
TWI344955B (en) | 2003-03-14 | 2011-07-11 | Ono Pharmaceutical Co | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient |
SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
EP2364982A1 (en) | 2003-04-18 | 2011-09-14 | ONO Pharmaceutical Co., Ltd. | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof |
US20070043079A1 (en) * | 2003-04-18 | 2007-02-22 | Hiromu Habashita | Heterocyclic compound containing nitrogen atom and use thereof |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
KR20060009390A (ko) * | 2003-06-13 | 2006-01-31 | 쉐링 악티엔게젤샤프트 | Ccr-5 길항제로서의 퀴놀릴 아미드 유도체 |
JP2007523864A (ja) | 2003-07-10 | 2007-08-23 | シェーリング コーポレイション | 3−ケトアルカン酸エステルから2−(アルコキシアルキリデン)−3−ケトアルカン酸エステルを調製および精製するためのプロセス |
SE0302956D0 (sv) * | 2003-11-07 | 2003-11-07 | Astrazeneca Ab | Chemical compounds |
US7498346B2 (en) * | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
EP1716156A2 (en) | 2004-02-10 | 2006-11-02 | F.Hoffmann-La Roche Ag | Chemokine ccr5 receptor modulators |
SE0400925D0 (sv) * | 2004-04-06 | 2004-04-06 | Astrazeneca Ab | Chemical compounds |
EP1734966B1 (en) | 2004-04-13 | 2013-07-31 | Incyte Corporation | Piperazinylpiperidine derivatives as chemokine receptor antagonists |
MXPA06014404A (es) | 2004-06-09 | 2007-02-19 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
JP4894518B2 (ja) | 2004-09-13 | 2012-03-14 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
EP1844037A1 (en) * | 2005-01-20 | 2007-10-17 | Pfizer Limited | Chemical compounds |
RU2007134259A (ru) * | 2005-02-16 | 2009-03-27 | Шеринг Корпорейшн (US) | Гетероциклические замещенные пиперазины, обладающие антагонистическим действием к cxcr3 |
AR055313A1 (es) * | 2005-02-23 | 2007-08-15 | Schering Corp | Derivados piperidinil piperidina utiles como inhibidores de receptores de quimioquinas. proceso de obtencion y composiciones farmaceuticas |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US20110052612A1 (en) | 2005-05-31 | 2011-03-03 | Ono Pharmaceutical Co., Ltd. | Spiropiperidine compound and medicinal use thereof |
US7665658B2 (en) | 2005-06-07 | 2010-02-23 | First Data Corporation | Dynamic aggregation of payment transactions |
CA2615650A1 (en) | 2005-07-21 | 2007-01-25 | Astrazeneca Ab | Novel piperidine derivatives |
JP2009515826A (ja) | 2005-10-19 | 2009-04-16 | エフ.ホフマン−ラ ロシュ アーゲー | フェニル−アセトアミドnnrt阻害剤 |
EP1957530A2 (en) | 2005-10-21 | 2008-08-20 | Novartis AG | Human antibodies against il13 and therapeutic uses |
PT1942108E (pt) | 2005-10-28 | 2013-10-24 | Ono Pharmaceutical Co | Composto com um grupo básico e a sua utilização |
US8168783B2 (en) | 2005-11-18 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
GB0525671D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
RU2008140144A (ru) | 2006-03-10 | 2010-04-20 | Оно Фармасьютикал Ко., Лтд. (Jp) | Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента |
WO2007116313A2 (en) * | 2006-04-12 | 2007-10-18 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
DK2013211T3 (da) | 2006-04-21 | 2012-07-02 | Novartis Ag | Purinderivater til anvendelse som adenosin-A2A-receptoragonister |
US8618122B2 (en) | 2006-05-16 | 2013-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having acidic group which may be protected, and use thereof |
WO2008016006A1 (en) | 2006-07-31 | 2008-02-07 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
KR101401811B1 (ko) | 2006-08-16 | 2014-05-29 | 에프. 호프만-라 로슈 아게 | 비-뉴클레오사이드 역전사효소 저해제 |
DE602007013441D1 (de) | 2006-09-29 | 2011-05-05 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
ES2550152T3 (es) | 2006-12-13 | 2015-11-04 | F. Hoffmann-La Roche Ag | Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa |
DK2104535T3 (da) | 2007-01-10 | 2011-04-04 | Irm Llc | Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer |
CA2682639A1 (en) | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
CA2685546A1 (en) | 2007-05-07 | 2008-11-13 | Novartis Ag | Organic compounds |
NZ585789A (en) | 2007-12-10 | 2012-03-30 | Novartis Ag | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel |
CA2716838C (en) * | 2008-02-29 | 2014-01-07 | Schering Corporation | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
MX2010013675A (es) | 2008-06-10 | 2011-02-15 | Novartis Ag | Derivados de pirazina como bloqueadores del canal de sodio epitelial. |
WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
EP2464649A1 (en) | 2009-08-12 | 2012-06-20 | Novartis AG | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
NZ598220A (en) | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
MX2012002179A (es) | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
EP2490687A1 (en) | 2009-10-22 | 2012-08-29 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
HUE031710T2 (en) | 2010-07-14 | 2017-07-28 | Novartis Ag | IP receptor agonist heterocyclic compounds |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物 |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
BR112014006223A8 (pt) | 2011-09-15 | 2018-01-09 | Novartis Ag | 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação |
EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
US9034879B2 (en) | 2011-09-16 | 2015-05-19 | Novartis Ag | Heterocyclic compounds for the treatment of CF |
US9187451B2 (en) | 2011-11-18 | 2015-11-17 | Heptares Therapeutics Limited | Muscarinic M1 receptor agonists |
JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン, エルエルシー | Mtor阻害剤を使用する強化された治療レジメン |
EP2802582A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
EP2802583A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
US9115129B2 (en) | 2012-01-13 | 2015-08-25 | Novartis Ag | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists |
JP6058698B2 (ja) | 2012-01-13 | 2017-01-11 | ノバルティス アーゲー | Ip受容体アゴニストの塩 |
WO2013105057A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
US20140378463A1 (en) | 2012-01-13 | 2014-12-25 | Novartis Ag | IP receptor agonist heterocyclic compounds |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
MX371119B (es) | 2012-04-03 | 2020-01-17 | Novartis Ag | Productos de combinacion con los inhibidores de cinasa de tirosina y su uso. |
JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited | ムスカリンm4受容体アゴニストとしてのピペリジン−1−イル及びアゼピン−1−イルカルボキシレート |
WO2014125413A1 (en) | 2013-02-13 | 2014-08-21 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
JP2016512835A (ja) | 2013-03-15 | 2016-05-09 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせ及びそれらの使用 |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
CA2934132A1 (en) | 2013-12-19 | 2015-06-25 | Bayer Pharma Aktiengesellschaft | Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists |
JOP20200052A1 (ar) | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c |
AP2016009303A0 (en) | 2013-12-19 | 2016-06-30 | Bayer Pharma AG | Substituted piperidinyl-tetrahydroquinolines |
CN106029657A (zh) | 2013-12-19 | 2016-10-12 | 拜耳制药股份公司 | 作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物 |
ES2761569T3 (es) | 2014-04-24 | 2020-05-20 | Novartis Ag | Derivados aminopiridínicos como inhibidores de fosfatidilinositol 3-cinasas |
JP6404944B2 (ja) | 2014-04-24 | 2018-10-17 | ノバルティス アーゲー | ホスファチジルイノシトール3−キナーゼ阻害薬としてのピラジン誘導体 |
EA032075B1 (ru) | 2014-04-24 | 2019-04-30 | Новартис Аг | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
JP6526789B2 (ja) | 2014-07-31 | 2019-06-05 | ノバルティス アーゲー | 組み合わせ療法 |
GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
AU2020290094B2 (en) | 2019-06-10 | 2024-01-18 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis |
AR119819A1 (es) | 2019-08-28 | 2022-01-12 | Novartis Ag | Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
NZ333513A (en) * | 1996-07-10 | 2000-04-28 | Schering Corp | 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists |
WO1998004125A1 (en) * | 1996-07-25 | 1998-02-05 | Terence George Mackay | Improvements in or relating to fishing |
BR9711061A (pt) * | 1996-08-15 | 1999-08-17 | Schering Corp | Antagonistas muscarinicos de eter |
JP2002510327A (ja) * | 1997-07-25 | 2002-04-02 | メルク エンド カンパニー インコーポレーテッド | 環状アミンケモカイン受容体活性調節剤 |
-
2000
- 2000-05-01 EP EP05010590A patent/EP1659111A3/en not_active Withdrawn
- 2000-05-01 DK DK00926487T patent/DK1175402T3/da active
- 2000-05-01 ES ES00926487T patent/ES2246233T3/es not_active Expired - Lifetime
- 2000-05-01 PL PL351412A patent/PL203117B1/pl not_active IP Right Cessation
- 2000-05-01 CN CNA2004100282860A patent/CN1524527A/zh active Pending
- 2000-05-01 CA CA002371587A patent/CA2371587C/en not_active Expired - Fee Related
- 2000-05-01 DE DE60021371T patent/DE60021371T2/de not_active Expired - Lifetime
- 2000-05-01 TR TR2001/03213T patent/TR200103213T2/xx unknown
- 2000-05-01 AU AU45010/00A patent/AU780983B2/en not_active Ceased
- 2000-05-01 SK SK1567-2001A patent/SK286968B6/sk not_active IP Right Cessation
- 2000-05-01 RU RU2001132635/04A patent/RU2266281C2/ru not_active IP Right Cessation
- 2000-05-01 NZ NZ514675A patent/NZ514675A/en not_active IP Right Cessation
- 2000-05-01 IL IL14574200A patent/IL145742A0/xx unknown
- 2000-05-01 WO PCT/US2000/011633 patent/WO2000066559A1/en active IP Right Grant
- 2000-05-01 SI SI200030719T patent/SI1175402T1/xx unknown
- 2000-05-01 CZ CZ20013941A patent/CZ301161B6/cs not_active IP Right Cessation
- 2000-05-01 PT PT00926487T patent/PT1175402E/pt unknown
- 2000-05-01 BR BR0010607-0A patent/BR0010607A/pt not_active Application Discontinuation
- 2000-05-01 AT AT00926487T patent/ATE299866T1/de not_active IP Right Cessation
- 2000-05-01 KR KR10-2001-7013862A patent/KR100439357B1/ko not_active IP Right Cessation
- 2000-05-01 CN CNB008071683A patent/CN1151131C/zh not_active Expired - Fee Related
- 2000-05-01 TR TR2004/02496T patent/TR200402496T2/xx unknown
- 2000-05-01 JP JP2000615390A patent/JP3894729B2/ja not_active Expired - Fee Related
- 2000-05-01 HU HU0203528A patent/HUP0203528A3/hu unknown
- 2000-05-01 EP EP00926487A patent/EP1175402B1/en not_active Expired - Lifetime
- 2000-05-02 AR ARP000102095A patent/AR023939A1/es unknown
- 2000-05-02 MY MYPI20001891A patent/MY141473A/en unknown
- 2000-05-02 EG EG20000563A patent/EG24533A/xx active
- 2000-05-02 PE PE2000000406A patent/PE20010113A1/es not_active Application Discontinuation
- 2000-05-02 TW TW089108325A patent/TWI283666B/zh active
- 2000-05-02 CO CO00031252A patent/CO5170522A1/es not_active Application Discontinuation
- 2000-08-05 SA SA00210270A patent/SA00210270B1/ar unknown
-
2001
- 2001-10-26 ZA ZA200108867A patent/ZA200108867B/xx unknown
- 2001-11-02 NO NO20015365A patent/NO322044B1/no not_active IP Right Cessation
-
2002
- 2002-02-02 HK HK02100825.9A patent/HK1039330B/zh not_active IP Right Cessation
-
2005
- 2005-05-31 AU AU2005202358A patent/AU2005202358B2/en not_active Ceased
- 2005-06-23 RU RU2005120376/15A patent/RU2005120376A/ru not_active Application Discontinuation
-
2006
- 2006-05-31 JP JP2006152916A patent/JP2006225407A/ja not_active Withdrawn
-
2011
- 2011-07-07 JP JP2011151208A patent/JP2011219493A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EG24533A (en) | Piperdine derivatives useful as CCR 5 antagonists | |
EG24136A (en) | Piperazine derivatives useful as ccr5 antagonists | |
EG24433A (en) | Novel benzolimidazole derivatives useful as antiproliferative agents | |
EP1206262A4 (en) | Y NEUROPEPTID ANTAGONISTS: SPIROISOQUINOLINONE DERIVATIVES | |
EP1235798A4 (en) | PIPERIDINYL SUBSTITUTED IN 1.4 EFFECTIVE AS ANTAGONIST NMDA / NR2B | |
GB9918180D0 (en) | Novel compositions | |
PL356990A1 (pl) | Pochodne izoksazolokarboksyamidu | |
GB9921037D0 (en) | Compositions | |
IL148623A0 (en) | Thienoisoxazolyl-and thienylpyrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists | |
EG22187A (en) | New composition | |
GB9904049D0 (en) | Rapidly-soluble compositions | |
HK1043590A1 (zh) | 毒蕈碱性拮抗物 | |
AU2673201A (en) | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | |
AP2001002273A0 (en) | Rescorcinol composition | |
GB2366984B (en) | Composition | |
GB9929622D0 (en) | Compositions | |
GB9903924D0 (en) | Cosmectic compositions | |
GB9904931D0 (en) | Compositions | |
GB2357714B (en) | Composition | |
GB9926833D0 (en) | Compositions | |
GB9904614D0 (en) | Piperidines | |
GB9918805D0 (en) | New heterocyclic pigments | |
GB9912423D0 (en) | Compositions | |
GB9905571D0 (en) | Compositions | |
GB9904599D0 (en) | Compositions |